Regencell Bioscience Holdings Limited (RGC)
USD 4.84
(-0.62%)
USD 4.84
(-0.62%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -4 Million | -4.96 Million | -5.26 Million | -767.31 Thousand | -726.57 Thousand | -390.99 Thousand |
| Net Income | -4.36 Million | -6.06 Million | -7.59 Million | -1.34 Million | -812.37 Thousand | -390.99 Thousand |
| Depreciation & Amortization | 745.58 Thousand | 769.68 Thousand | 604.39 Thousand | 26.45 Thousand | 9516.00 | - |
| Deferred income taxes | - | 1415.00 | - | - | - | - |
| Stock-based compensation | 449.31 Thousand | 922.62 Thousand | 2.75 Million | - | - | - |
| Change in working capital | -585.36 Thousand | -508.94 Thousand | -1.02 Million | 552.97 Thousand | 76.28 Thousand | - |
| Other non-cash items | -248 Thousand | -85.4 Thousand | -10.73 Thousand | 52.91 Thousand | 19.03 Thousand | - |
| Investing Cash Flow | 5.24 Million | 58.97 Thousand | -10.78 Million | - | -117.83 Thousand | - |
| Investments in PPE | -5376.00 | -27.39 Thousand | -780.87 Thousand | - | -117.83 Thousand | - |
| Acquisitions | - | 970.00 | - | - | - | - |
| Investment purchases | -5 Million | -10 Million | -10 Million | - | - | - |
| Sales/Maturities of investments | 10.24 Million | 10.08 Million | - | - | - | - |
| Other Investing Activities | - | 86.37 | -10 Thousand | - | - | - |
| Financing Cash Flow | 102.28 Thousand | 134.91 Thousand | 22.4 Million | 439.74 Thousand | 988.08 Thousand | 480.99 Thousand |
| Debt repayment | - | - | -431.96 Thousand | -612.05 Thousand | -988.08 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 22.67 Million | - | - | - |
| Other Financing Activities | 102.28 Thousand | 134.91 Thousand | -267.96 Thousand | 439.74 Thousand | 988.08 Thousand | 480.99 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -585.36 Thousand | -508.94 Thousand | -1.02 Million | 552.97 Thousand | 76.28 Thousand | - |
| Cash at beginning of period | 1.56 Million | 6.41 Million | 59.41 Thousand | 386.97 Thousand | 243.3 Thousand | 153.3 Thousand |
| Cash at end of period | 2.96 Million | 1.56 Million | 6.41 Million | 59.41 Thousand | 386.97 Thousand | 243.3 Thousand |
| Capital Expenditure | -5376.00 | -27.39 Thousand | -780.87 Thousand | - | -117.83 Thousand | - |
| Effect of forex changes on cash | 53.22 Thousand | -83.14 Thousand | - | - | - | - |
| Net cash flow / Change in cash | 1.39 Million | -4.85 Million | 6.35 Million | -327.56 Thousand | 143.67 Thousand | 90 Thousand |
| Free Cash Flow | -4 Million | -4.99 Million | -6.04 Million | -767.31 Thousand | -844.41 Thousand | -390.99 Thousand |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1033.31 | -1033.31 | -6.06 Million | -1321.88 | -1321.88 | -1613.69 |
| Depreciation & Amortization | - | - | 769.68 Thousand | 769.68 Thousand | - | - |
| Deferred income taxes | - | - | 1415.00 | - | - | - |
| Stock-based compensation | 100.00 | 100.00 | 922.62 Thousand | 15.00 | 15.00 | 450.00 |
| Change in working capital | - | - | -508.94 Thousand | - | - | - |
| Other non-cash items | 933.31 | 933.31 | -85.4 Thousand | 1306.88 | 1306.88 | 1163.69 |
| Investing Cash Flow | - | - | 58.97 Thousand | - | - | - |
| Investments in PPE | - | - | -27.39 Thousand | - | - | - |
| Acquisitions | - | - | 970.00 | - | - | - |
| Investment purchases | - | - | -10 Million | - | - | - |
| Sales/Maturities of investments | - | - | 10.08 Million | - | - | - |
| Other Investing Activities | - | - | 86.37 | - | - | - |
| Financing Cash Flow | - | - | 134.91 Thousand | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | 134.91 Thousand | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | -508.94 Thousand | - | - | - |
| Cash at beginning of period | - | - | 6.41 Million | 25.4 Thousand | - | 6.41 Million |
| Cash at end of period | - | - | 1.56 Million | 1.56 Million | 15.00 | 6.41 Million |
| Capital Expenditure | - | - | -27.39 Thousand | - | - | - |
| Effect of forex changes on cash | - | - | -83.14 Thousand | - | - | - |
| Net cash flow / Change in cash | - | - | -4.85 Million | 1.53 Million | 15.00 | 450.00 |
| Free Cash Flow | - | - | -4.99 Million | 1.53 Million | 15.00 | 450.00 |
METROPOLIS
002306
7247
CTD
LESHAIND
KBGCF